Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
EGFR-mutated lung cancer
Pharma
AstraZeneca buys lung cancer drug Zegfrovy from Dizal for $1.5B
AZ, which spun off Dizal in 2017, is tied with a China state-owned fund in holding the largest stakes in the biotech at a 23.4% share.
Angus Liu
Jul 14, 2026 9:57am
Dizal takes on J&J with first-line win in EGFR lung cancer type
May 29, 2026 8:00am
Dizal's Zegfrovy adds more pressure to J&J's Rybrevant
Mar 23, 2026 10:25am
J&J alleges trade secret theft by former staffer linked to Summit
Mar 16, 2026 10:44am
FDA approves J&J's new challenge to Tagrisso
Dec 18, 2025 10:40am
Akeso details ivonescimab's 1st overall survival win
Nov 7, 2025 11:30am
